Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS

Courtney V. Fletcher, Brian K. Goodroad, Larry M. Cummins, Keith Henry, Henry H. Balfour, Frank S. Rhame

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Hyperimmune anti-human immunodeficiency virus immunoglobin (HIVIG) is an intravenous immunoglobulin prepared from HIV-infected asymptomatic donuts with a CD4 cell count greater than 400 cells/μl and a high tiler of antibody to HIV-1 p24 protein. Twelve persons with AIDS received four doses of HIVIG (two at 50 mg/kg of body weight and then two at 200 mg/kg) every 28 days. Pharmacokinetics were evaluated by measurement of anti-p24 antibody. HIVIG was well tolerated, and all participants completed the study. Three subjects who were not receiving Pneumocystis carinii pneumonia (PCP) prophylaxis developed PCP. The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively. This study indicates that high tilers of anti-p24 antibody can be maintained with a monthly administration schedule of HIVIG and that short-term safety is acceptable. Comparisons to evaluate the therapeutic potential of HIVIG are justified.

Original languageEnglish (US)
Pages (from-to)1571-1574
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number7
DOIs
StatePublished - Jul 1997
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS'. Together they form a unique fingerprint.

  • Cite this